Palvella Therapeutics (NASDAQ:PVLA) Issues Quarterly Earnings Results

Palvella Therapeutics (NASDAQ:PVLA) posted its earnings results on Tuesday. The company reported ($1.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.35), Zacks reports.

Here are the key takeaways from Palvella Therapeutics’ conference call:

• QTORIN rapamycin’s NDA remains on track for completion in the second half of 2026, with potential FDA approval in the first half of 2027. FDA granted rolling review, supported by the product’s Fast Track and Breakthrough Therapy designations.
• The company highlighted strong phase III SELVA results in microcystic lymphatic malformations, including improvement in 95% of patients at week 24 and a favorable safety profile. Palvella plans to pursue a broad label that includes pediatric patients and is targeting a potential first-line therapy.
• Palvella is expanding its commercial infrastructure ahead of a potential launch, including increasing its planned sales force to approximately 40 representatives, building medical affairs and patient-support teams, and engaging more than 200 of 400 targeted clinics.
• The pipeline continues to advance, with a phase III study in cutaneous venous malformations expected to begin in the fourth quarter of 2026, a phase II angiokeratoma study already underway, and a phase II DSAP study expected to start in the fourth quarter. The company expects additional QTORIN program announcements later this year.
• FDA did not grant Breakthrough Therapy Designation for the cutaneous venous malformation program based on the initial 12-week data package. Palvella plans to resubmit using 24-week efficacy results and qualitative patient data, while increased commercial and medical investments raised expected 2026 cash expenses to approximately $85 million-$95 million.

Palvella Therapeutics Price Performance

PVLA stock traded down $0.96 during midday trading on Thursday, reaching $153.95. The company had a trading volume of 57,676 shares, compared to its average volume of 276,349. The company has a market capitalization of $2.21 billion, a price-to-earnings ratio of -31.72 and a beta of -0.17. The stock has a 50 day moving average price of $132.19 and a 200-day moving average price of $119.36. Palvella Therapeutics has a 1-year low of $37.33 and a 1-year high of $161.38.

Insiders Place Their Bets

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $110.73, for a total transaction of $476,360.46. Following the sale, the chief operating officer directly owned 2,154 shares in the company, valued at $238,512.42. This represents a 66.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 17.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Palvella Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Group One Trading LLC increased its stake in shares of Palvella Therapeutics by 151.5% in the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after purchasing an additional 200 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Palvella Therapeutics by 11.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,090 shares of the company’s stock worth $429,000 after buying an additional 433 shares during the last quarter. Bank of America Corp DE boosted its stake in Palvella Therapeutics by 12.3% in the third quarter. Bank of America Corp DE now owns 4,689 shares of the company’s stock valued at $294,000 after buying an additional 515 shares in the last quarter. Deutsche Bank AG boosted its stake in Palvella Therapeutics by 8.7% in the fourth quarter. Deutsche Bank AG now owns 6,594 shares of the company’s stock valued at $690,000 after buying an additional 528 shares in the last quarter. Finally, Russell Investments Group Ltd. bought a new position in Palvella Therapeutics in the third quarter valued at about $36,000. 40.11% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently commented on PVLA. Canaccord Genuity Group set a $232.00 price target on shares of Palvella Therapeutics in a research report on Wednesday. Stephens restated an “overweight” rating and set a $220.00 target price on shares of Palvella Therapeutics in a research report on Thursday, May 21st. Chardan Capital upgraded shares of Palvella Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. Wall Street Zen cut shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Palvella Therapeutics in a research report on Monday, June 29th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $209.14.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical?stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small?molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil? and complement?mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.